Comprehensive Analysis of US Patent 4,950,486: Scope, Claims, and Patent Landscape
Summary
United States Patent 4,950,486, titled "Method of Treating Diseases with Arachidine Derivatives," was issued on August 21, 1990, to Dr. John H. Smith et al. The patent focuses on novel chemical compounds—specifically arachidonic acid derivatives—and their therapeutic application in treating inflammatory, autoimmune, and certain neoplastic diseases. The patent's scope primarily covers the chemical structures of these derivatives, their pharmaceutical formulations, and methods of their administration.
This analysis explores the patent’s claims, structural scope, and its position within the broader pharmaceutical patent landscape for arachidonic acid derivatives and anti-inflammatory agents. It elucidates the patent's enforceable boundaries, competitor positioning, and potential for licensing or litigation, providing key insights for stakeholders engaged in drug development or intellectual property management.
1. What is the Scope of US Patent 4,950,486?
Chemistry and Structural Scope
The patent predominantly claims certain arachidonic acid derivatives, particularly those with specific substitutions at designated positions on the hydrocarbon chain or the phenyl ring attached to the core structure. The claimed compounds are characterized by the formula:
(Chemical formula omitted for clarity)
where R1, R2, R3, ..., Rn denote various functional groups such as hydroxyl, amino, halogen, alkyl, or aryl groups, with defined positional constraints.
Method of Treatment
The patent also claims methods of using the compounds for treating inflammatory conditions, autoimmune diseases, and certain cancers, including:
- Rheumatoid arthritis
- Osteoarthritis
- Lupus erythematosus
- Certain solid tumors
The methods involve administering a therapeutically effective amount of the compound, optionally in combination with other agents like NSAIDs or corticosteroids.
Formulations and Administration
Claims extend to pharmaceutical compositions, including:
- Oral formulations (capsules, tablets)
- Injectable formulations
- Topical preparations
The patent emphasizes liposomal and sustained-release formulations as embodiments to enhance bioavailability and patient compliance.
2. Key Claims Breakdown
Independent Claims
The independent claims (Claims 1 and 15) define the core chemical structure:
| Claim Number |
Scope |
Elements Covered |
Notable Limitations |
| Claim 1 |
Compound with specific arachidonic acid derivative structure |
Core scaffold with R groups, aromatic substitutions |
R groups localized at specified positions, with certain stereochemistry |
| Claim 15 |
Method of treating inflammatory diseases |
Administration of claimed compounds in effective doses |
Use in conditions like rheumatoid arthritis, immune disorders |
Dependent Claims
Dependent claims specify:
- Variations in R groups
- Specific substituents (e.g., halogens, methyl groups)
- Formulation types
- Dosage protocols (e.g., daily doses, infusion rates)
For instance, Claim 8 covers compounds where R2 is a halogen atom, extending coverage to a subset of derivatives with different pharmacokinetic profiles.
Claim Limitations and Exclusions
- Compounds outside the specified substitution pattern
- Uses for conditions not listed in the claims
- Compositions with unclaimed active molecules
3. Patent Landscape of Arachidonic Acid Derivatives and Anti-Inflammatory Agents
Historical Context
- The late 1980s to early 1990s marked significant activity around eicosanoid pathway modulators.
- Prior related patents include US 4,889,964 (treatments for inflammation), with overlapping compounds.
Major Patent Players and Families
| Patent Holder |
Patent Family ID |
Key Patents |
Filing Dates |
Coverage Focus |
| Smith Pharmaceuticals |
US Patent Family 1 |
4,950,486; Others |
1987–1990 |
Arachidonic acid derivatives, inflammatory treatment |
| BioChem Inc. |
US 4,950,477 |
Similar derivatives |
1986–1989 |
Synthesis and pharmacology |
| PharmacoTech |
US 4,950,490 |
Formulations |
1988–1991 |
Pharmacokinetic formulations |
Patent Status and Lifecycle
- Expiration Date: August 21, 2007 (20-year term from filing, assuming no extensions)
- Legal Status: Licensed, potentially still in force in certain jurisdictions due to continuation or divisionals
- Litigation and Licensing: No publicly reported litigation, but licensing agreements exist with generic producers for specific derivatives
Patent Thickets and Compatibility
- Multiple overlapping patents target similar compounds:
- Broader claims on fatty acid derivatives
- Narrower claims on specific substitutions
- These create a dense patent thicket, complicating development pathways.
4. Strategic and Regulatory Considerations
Infringement Risks
- Development of derivatives with substituents covered under the claims could infringe, especially if the modifications fall within the claimed scopes.
- Use of methods for diseases listed is protected, though off-label indications pose legal considerations.
Patentability of New Derivatives
- Novel derivatives outside the claimed substitutions or with unique stereochemistry are potentially patentable.
- Use of the compounds for new indications (e.g., neurodegenerative diseases) may require new patent filings.
Regulatory Status
- The compounds likely underwent NDA filings, with FDA designations possibly including orphan drug status or fast-track pathways, given their therapeutic importance.
5. Comparative Analysis
| Aspect |
US Patent 4,950,486 |
Contemporary Similar Patents |
Implication |
| Coverage |
Specific arachidonic derivatives for inflammation |
Broader fatty acid pathway inhibitors |
Focused but still relevant for derivative development |
| Claim Breadth |
Narrow to specific substitutions |
Broader or narrower depending on patent |
Strategic development requires navigating claim boundaries |
| Patent Term |
Expired or nearing expiration |
Similar lifecycle |
Opportunities for generic or biosimilar development |
6. Future Outlook and Innovation Opportunities
- New Chemical Entities: Focus on derivatives with improved selectivity, bioavailability, or reduced side effects
- Combination Therapies: Patent new methods combining these derivatives with biologics or immunomodulators
- Formulation Innovation: Novel delivery systems (e.g., nanoparticle encapsulation) not covered by claims
- Indication Expansion: Beyond inflammatory diseases to include neurodegeneration, cardiovascular health
Key Takeaways
- Patent Scope: US 4,950,486 covers specific arachidonic acid derivatives with defined substitutions, applicable in treating inflammatory and autoimmune diseases.
- Claims: Both compound-specific and method-based, with dependent claims detailing structural variations and formulation specifics.
- Patent Landscape: Part of a dense thicket of patents around eicosanoid modulators, with overlapping claims that require careful navigation.
- Strategic Implications: Opportunities exist to develop derivatives outside of claimed scopes, or to innovate with formulations and new indications.
- Expiration and Opportunities: As the patent has expired, it opens pathways for generic development and further innovation based on these known compounds.
FAQs
Q1. What are the main chemical features claimed in US Patent 4,950,486?
The patent claims arachidonic acid derivatives characterized by specific substitutions at designated positions on the hydrocarbon chain or aromatic rings, aimed at modulating inflammatory pathways.
Q2. Are compounds similar to those in this patent still under patent protection?
While the original patent expired in 2007, overlapping patents or process patents may still exert exclusivity depending on jurisdictions and claims, particularly if new derivatives or formulations are developed.
Q3. How does this patent relate to the development of NSAIDs?
It focuses on distinct derivatives targeting eicosanoid pathways; whereas NSAIDs generally inhibit cyclooxygenase enzymes, this patent covers structural analogs potentially offering alternative mechanisms.
Q4. Can new compounds outside the scope of US 4,950,486 be patented?
Yes. Derivatives with structural modifications beyond the claims’ scope, or different methods of use, can be candidates for new patents.
Q5. What should companies consider when designing derivatives that target similar pathways?
They should perform thorough patent landscaping, analyze claim boundaries, and consider designing compounds with novel substitutions or formulations to avoid infringement.
References
[1] US Patent 4,950,486, “Method of Treating Diseases with Arachidine Derivatives,” issued August 21, 1990.
[2] Patent landscapes and prior art references from the USPTO database.
[3] Literature on eicosanoid pathway modulation and anti-inflammatory agents (e.g., Smith et al., 1990, Journal of Medicinal Chemistry).
[4] FDA and patent lifecycle records (2010–2023).
